Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074728 | 0.92 | PDE5A (0.56) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL3933107 | 0.92 | PDE5A (0.53) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL4064304 | 0.91 | PDE5A (0.56) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL4068415 | 0.90 | PDE5A (0.57) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL3931339 | 0.89 | PDE5A (0.58) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL4065528 | 0.89 | PDE5A (0.53) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL4069662 | 0.88 | PDE5A (0.57) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL4064208 | 0.88 | PDE5A (0.63) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL4073215 | 0.88 | PDE5A (0.54) | PDE5ACLK4MEN1KMT2AALDH1A1 | |
| SCHEMBL3933679 | 0.88 | CLK4 (0.59) | PDE5ACLK4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | PDE5A 1018/4885CLK4 4484/4885MEN1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.